Gemoscan Canada, Inc. ("Gemoscan" or the "Corporation") – (TSX-V:GES) (MUN:1GE) wishes to announce that, subject to final regulatory approval, it has entered into a secured loan agreement with a non-arm's length party (the "Lender"). The Lender has provided the Corporation a $350,000 loan (the "Loan"), bearing interest at a rate of 9% per annum and which matures on April 5, 2014. Additionally, in connection with the Loan, the Lender will receive a bonus of 717,948 Class A Shares (the "Shares") in the capital of the Corporation at a price of $0.0975 per Share. All Shares are subject to a statutory four month plus one day hold period from April 5, 2014.

The Corporation also wishes to announce that, pursuant to its press release dated December 4, 2012, effective April 5, 2013 it has fully discharged the loan referenced in its December 4, 2012 press release.

The transaction is exempt from the valuation and minority shareholder approval requirements of Multilateral Instrument 61-101 - Protection Of Minority Security Holders In Special Transactions, which is incorporated by reference into TSX Venture Exchange Policy 5.9, Protection of Minority Security Holders in Special Transactions ("MI 61-101"). The Corporation is relying on the exemptions set out in 5.5(a) and 5.7(1)(a) of MI 61-101 as the fair market value of the transaction is not more than 25% of the Corporation's current market capitalization.

About Gemoscan Canada, Inc.

Gemoscan is an industry leader in food intolerance management and maintains a first-to-market position with Canada wide distribution through select retail partners. Founded in 2003, using its proprietary patented technology, Gemoscan develops, owns and markets comprehensive food sensitivity and dietary management solutions for consumers, including the HEMOCODE™ Food Intolerance System and the MenuWise™ Food Intolerance Plan, personalized naturopathically supervised nutritional programs that promote well-being. Gemoscan is the first and only provider to commercialize a food intolerance management solution directly to consumers in partnership with retailers, and today offers the most comprehensive services available.

Gemoscan Canada, Inc. trades its shares on the Toronto Venture Exchange under the symbol GES and is quoted on the Munich, Frankfurt and Stuttgart Stock Exchanges under the symbol 1GE.

Forward-Looking Information

This news release contains certain "forward-looking information". All statements, other than statements of historical fact that address activities, events or developments that Gemoscan believes, expects or anticipates will or may occur in the future. These forward-looking statements reflect the current expectations or beliefs of Gemoscan based on information currently available to Gemoscan. Forward- looking statements are subject to a number of signify cant risks and uncertainties and other factors that may cause the actual results of Gemoscan to differ materially from those discussed in the forward- looking statements, and even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on Gemoscan. Any forward-looking statement speaks only as of the date on which it is made and, except as may be required by applicable securities laws, Gemoscan disclaims any intent or obligation to update any forward-looking statement, whether as a result of new information, future events or results or otherwise. Although Gemoscan believes that the assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance and accordingly undue reliance should not be put on such statements due to the inherent uncertainty therein.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

CONTACT: Company:
         Brian Kalish
         Chief Executive Officer
         Gemoscan Canada, Inc.
         
         416.650.1200
         bkalish@hemocode.com
         www.gemoscan.com